Biotech · Private company
Quince Therapeutics S.p.A.
Track this companyFree. Adds Quince Therapeutics S.p.A. to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Dexamethasone sodium phosphatePhase 3 · Ataxia TelangiectasiaClinicalTrials.gov · fetched Nov 12, 2026
- EryDex High dose DSPPhase 3 · Nervous System DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- EryDex Low dose DSPPhase 3 · Nervous System DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- EryDex SystemPhase 3 · Ataxia TelangiectasiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Open-Label Extension of EryDex Study IEDAT-04-2022PHASE3 · TERMINATED · started Dec 11, 2024ClinicalTrials.gov NCT06664853 · fetched Nov 12, 2026
- Evaluate the Neurological Effects of EryDex on Subjects With A-TPHASE3 · COMPLETED · started Jun 24, 2024ClinicalTrials.gov NCT06193200 · fetched Nov 12, 2026
- Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 StudyPHASE3 · TERMINATED · started Jun 12, 2018ClinicalTrials.gov NCT03563053 · fetched Nov 12, 2026
- Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia PatientsPHASE3 · COMPLETED · started Mar 2, 2017ClinicalTrials.gov NCT02770807 · fetched Nov 12, 2026